Dickkopf-1 (DKK1) blockade mitigates osteogenesis imperfecta (OI) related bone disease

Abstract Background The current treatment of osteogenesis imperfecta (OI) is imperfect. Our study thus delves into the potential of using Dickkopf-1 antisense (DKK1-AS) to treat OI. Methods We analysed serum DKK1 levels and their correlation with lumbar spine and hip T-scores in OI patients. Compara...

Full description

Saved in:
Bibliographic Details
Main Authors: Jih-Yang Ko (Author), Feng-Sheng Wang (Author), Wei-Shiung Lian (Author), Fu-Shine Yang (Author), Jeng-Wei Chen (Author), Po-Hua Huang (Author), Chin-Yi Liao (Author), Shu-Jui Kuo (Author)
Format: Book
Published: BMC, 2024-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_276d3cc336804daa9c83b2dba42ea14d
042 |a dc 
100 1 0 |a Jih-Yang Ko  |e author 
700 1 0 |a Feng-Sheng Wang  |e author 
700 1 0 |a Wei-Shiung Lian  |e author 
700 1 0 |a Fu-Shine Yang  |e author 
700 1 0 |a Jeng-Wei Chen  |e author 
700 1 0 |a Po-Hua Huang  |e author 
700 1 0 |a Chin-Yi Liao  |e author 
700 1 0 |a Shu-Jui Kuo  |e author 
245 0 0 |a Dickkopf-1 (DKK1) blockade mitigates osteogenesis imperfecta (OI) related bone disease 
260 |b BMC,   |c 2024-05-01T00:00:00Z. 
500 |a 10.1186/s10020-024-00838-3 
500 |a 1528-3658 
520 |a Abstract Background The current treatment of osteogenesis imperfecta (OI) is imperfect. Our study thus delves into the potential of using Dickkopf-1 antisense (DKK1-AS) to treat OI. Methods We analysed serum DKK1 levels and their correlation with lumbar spine and hip T-scores in OI patients. Comparative analyses were conducted involving bone marrow stromal cells (BMSCs) and bone tissues from wild-type mice, untreated OI mice, and OI mice treated with DKK1-ASor DKK1-sense (DKK1-S). Results Significant inverse correlations were noted between serum DKK1 levels and lumbar spine (correlation coefficient = − 0.679, p = 0.043) as well as hip T-scores (correlation coefficient = − 0.689, p = 0.042) in OI patients. DKK1-AS improved bone mineral density (p = 0.002), trabecular bone volume/total volume fraction (p < 0.001), trabecular separation (p = 0.010), trabecular thickness (p = 0.001), trabecular number (p < 0.001), and cortical thickness (p < 0.001) in OI mice. DKK1-AS enhanced the transcription of collagen 1α1, osteocalcin, runx2, and osterix in BMSC from OI mice (all p < 0.001), resulting in a higher von Kossa-stained matrix area (p < 0.001) in ex vivo osteogenesis assays. DKK1-AS also reduced osteoclast numbers (p < 0.001), increased β-catenin and T-cell factor 4 immunostaining reactivity (both p < 0.001), enhanced mineral apposition rate and bone formation rate per bone surface (both p < 0.001), and decreased osteoclast area (p < 0.001) in OI mice. DKK1-AS upregulated osteoprotegerin and downregulated nuclear factor-kappa B ligand transcription (both p < 0.001). Bone tissues from OI mice treated with DKK1-AS exhibited significantly higher breaking force compared to untreated OI mice (p < 0.001). Conclusions Our study elucidates that DKK1-AS has the capability to enhance bone mechanical properties, restore the transcription of osteogenic genes, promote osteogenesis, and inhibit osteoclastogenesis in OI mice. 
546 |a EN 
690 |a Osteogenesis imperfecta (OI) 
690 |a Dickkopf-1 (DKK1) 
690 |a β-Catenin 
690 |a T-cell factor 4 (TCF4) 
690 |a Wnt3a 
690 |a Osteoprotegerin (OPG) 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Biochemistry 
690 |a QD415-436 
655 7 |a article  |2 local 
786 0 |n Molecular Medicine, Vol 30, Iss 1, Pp 1-20 (2024) 
787 0 |n https://doi.org/10.1186/s10020-024-00838-3 
787 0 |n https://doaj.org/toc/1528-3658 
856 4 1 |u https://doaj.org/article/276d3cc336804daa9c83b2dba42ea14d  |z Connect to this object online.